Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer

NCT02042443 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02042443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02042443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2014
Completion date
April 30, 2017
Enrollment
53 (actual)
Sites
295

Conditions

As the registry lists them; a condition with its own page is linked.

adult cholangiocarcinoma, advanced adult hepatocellular carcinoma, bclc stage c adult hepatocellular carcinoma, bclc stage d adult hepatocellular carcinoma, hilar cholangiocarcinoma, localized non-resectable adult liver carcinoma, recurrent adult liver carcinoma, recurrent childhood liver cancer, recurrent extrahepatic bile duct carcinoma, recurrent gallbladder carcinoma, stage ii gallbladder cancer, stage iii childhood hepatocellular carcinoma, stage iiia gallbladder cancer, stage iiib gallbladder cancer, stage iv childhood hepatocellular carcinoma, stage iv distal bile duct cancer, stage iva gallbladder cancer, stage ivb gallbladder cancer, unresectable extrahepatic bile duct carcinoma